Amgen (NASDAQ:AMGN) Downgraded to “Hold” Rating by Freedom Capital

Freedom Capital cut shares of Amgen (NASDAQ:AMGN) from a strong-buy rating to a hold rating in a research note published on Thursday morning,Zacks.com reports.

Other equities analysts have also recently issued research reports about the stock. HSBC reaffirmed a “buy” rating and issued a $425.00 price target on shares of Amgen in a research report on Wednesday, December 10th. Wall Street Zen lowered Amgen from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 7th. UBS Group upped their price target on Amgen from $380.00 to $390.00 and gave the stock a “buy” rating in a report on Monday, January 26th. DZ Bank increased their price target on Amgen from $335.00 to $364.00 in a research report on Monday, November 10th. Finally, Citigroup lifted their price objective on shares of Amgen from $315.00 to $345.00 and gave the stock a “neutral” rating in a report on Wednesday, February 4th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $354.04.

Amgen Price Performance

Shares of AMGN opened at $369.19 on Thursday. The business’s fifty day moving average is $337.47 and its 200 day moving average is $313.61. Amgen has a 12-month low of $261.43 and a 12-month high of $385.12. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The stock has a market cap of $198.80 billion, a P/E ratio of 25.94, a P/E/G ratio of 3.75 and a beta of 0.46.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. During the same quarter in the previous year, the business posted $5.31 EPS. Amgen’s quarterly revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Sell-side analysts anticipate that Amgen will post 20.62 earnings per share for the current fiscal year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be paid a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Friday, February 13th. This is a positive change from Amgen’s previous quarterly dividend of $2.38. Amgen’s dividend payout ratio (DPR) is presently 66.90%.

Insiders Place Their Bets

In related news, SVP Nancy A. Grygiel sold 3,139 shares of the stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the completion of the transaction, the senior vice president owned 7,225 shares in the company, valued at approximately $2,436,703.50. This represents a 30.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.76% of the company’s stock.

Institutional Investors Weigh In On Amgen

Several large investors have recently added to or reduced their stakes in AMGN. CreativeOne Wealth LLC lifted its holdings in Amgen by 7.9% during the fourth quarter. CreativeOne Wealth LLC now owns 17,159 shares of the medical research company’s stock valued at $5,616,000 after purchasing an additional 1,255 shares during the last quarter. Burton Enright Welch bought a new stake in shares of Amgen in the fourth quarter valued at approximately $254,000. Transamerica Financial Advisors LLC raised its position in shares of Amgen by 12.7% in the fourth quarter. Transamerica Financial Advisors LLC now owns 673 shares of the medical research company’s stock valued at $220,000 after purchasing an additional 76 shares during the period. Volterra Technologies LP lifted its stake in shares of Amgen by 405.4% during the 4th quarter. Volterra Technologies LP now owns 3,744 shares of the medical research company’s stock valued at $1,225,000 after buying an additional 4,970 shares in the last quarter. Finally, Fortis Capital Management LLC boosted its holdings in Amgen by 18.0% in the 4th quarter. Fortis Capital Management LLC now owns 2,568 shares of the medical research company’s stock worth $841,000 after buying an additional 391 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: European Commission approval for Uplinza (amifampridine) for generalized myasthenia gravis expands Amgen’s labelled indications in Europe and supports incremental near-term revenue potential for the product. Amgen wins EC approval for Uplinza in gMG
• Positive Sentiment: Amgen announced an increase to its dividend to $2.52, which boosts yield and signals management confidence in cash flow — typically supportive for a large-cap, dividend-oriented stock. Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.52
• Positive Sentiment: Unusually large call-option activity (roughly 320,232 calls bought) points to short-term bullish positioning by some investors, which can amplify upside moves in the stock. (No source link provided in feed)
• Neutral Sentiment: Amgen will present at Citi’s 2026 Virtual Oncology Leadership Summit — a standard investor relations event that raises visibility on oncology programs but is not intrinsically catalytic. AMGEN TO PRESENT AT CITI’S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT
• Neutral Sentiment: Analyst notes are mixed: Argus reiterated a Buy with a $400 target while Guggenheim reaffirmed a Hold — this provides conflicting signals but keeps the stock in analysts’ focus. Here’s What Argus Research and Guggenheim Are Saying About Amgen Inc. (AMGN)
• Neutral Sentiment: Industry coverage (CNBC) on pharma’s resetting priorities — pricing, pipelines and patent cliffs — is a sector-level backdrop that could affect sentiment for large-cap drugmakers like Amgen but is not company-specific. Prices, pipelines and patent cliffs: Inside pharma’s big reset
• Neutral Sentiment: Recent entries on short interest in the data feed appear to be reporting zero shares / NaN changes (likely a reporting glitch) and do not signal a meaningful rise in short positioning. (No link provided)

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.